Table 1.
Baseline demographics and clinical characteristics.
| Demographic | N (%) |
|---|---|
| Median Age (range) – years | 78 (75–92) |
| ECOG PS | |
| 0 | 65 (23.6) |
| 1 | 153 (55.4) |
| 2 | 51 (18.5) |
| 3 | 2 (0.7) |
| 4 | 1 (0.4) |
| Not recorded | 4 (1.4) |
| ACCI | |
| <10 | 186 (67.4) |
| >10 | 87 (31.5) |
| Not recorded | 3 (1.1) |
| BMI | |
| underweight <18.5 | 4 (1.4) |
| normal 18.5–24.9 | 78 (28.2) |
| overweight 25–29.9 | 77 (27.9) |
| obesity ≥30 | 56 (20.3) |
| Not recorded | 61 (22.1) |
| ER status (Allred score) | |
| strongly-positive (score 6–8) | 257 (93.1) |
| weakly-positive (score 3–5) | 7 (2.5) |
| Not Recorded | 12 (4.3) |
| Burden of metastatic disease | |
| visceral metastases – Yes | 147 (53.1) |
| - No | 127 (45.8) |
| Bone metastases – Yes | 180 (65.0) |
| - No | 95 (34.3) |
| Bone only metastases | 93 (33.7) |
| Bone + visceral metastases | 85 (30.8) |
| No. of organs involved with metastases | |
| 0 | 15 (5.4) |
| 1 | 109 (39.4) |
| 2 | 89 (32.1) |
| 3 or more | 59 (21.7) |
| Presentation | |
| De Novo metastatic disease | 119 (43.1) |
| Recurrence | 156 (56.5) |
| Not recorded | 1 (0.4) |
| AI used with palbociclib | |
| letrozole | 246 (89.1) |
| anastrozole | 18 (6.5) |
| exemestane | 10 (3.6) |
| Not recorded | 2 (0.7) |
| Starting dose of palbociclib | |
| 125 mg | 243 (88.0) |
| 100 mg | 29 (10.5) |
| 75 mg | 3 (1.1) |
| Not recorded | 1 (0.4) |
Abbreviations: ECOG = Eastern Cooperative Oncology Group; PS = performance status; ACCI = Age-adjusted Charlson Comorbidity Index; BMI = body mass index; ER = oestrogen receptor; AI = aromatase inhibitor.